• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

联合放疗和免疫检查点阻断对腔上皮样亚型小鼠膀胱癌模型中免疫记忆的影响。

Effects of combined radiotherapy with immune checkpoint blockade on immunological memory in luminal-like subtype murine bladder cancer model.

机构信息

Cancer Research Program, Research Institute of McGill University Health Center, Montréal, QC, Canada.

Division of Urology, Department of Surgery, McGill University Health Center, Montréal, QC, Canada.

出版信息

Cancer Biol Ther. 2024 Dec 31;25(1):2365452. doi: 10.1080/15384047.2024.2365452. Epub 2024 Jun 11.

DOI:10.1080/15384047.2024.2365452
PMID:38860746
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11174127/
Abstract

MIBC is a highly lethal disease, and the patient survival rate has not improved significantly over the last decades. UPPL is a cell line that can be used to recapitulate the luminal-like molecular subtype of bladder cancer and to discover effective treatments to be translated in patients. Here, we investigate the effects of combinational treatments of radiotherapy and immunotherapy in this recently characterized UPPL tumor-bearing mice. We first characterized the baseline tumor microenvironment and the effect of radiation, anti-PD-L1, and combinatorial treatments. Then, the mice were re-challenged with a second tumor (rechallenged tumor) in the contralateral flank of the first tumor to assess the immunological memory. Radiation slowed down the tumor growth. All treatments also decreased the neutrophil population and increased the T cell population. Anti-PD-L1 therapy was not able to synergize with radiation to further delay tumor growth. Furthermore, none of the treatments were able to generate immune memory. The treatments were not sufficient to induce a significant and lasting pool of memory cells. We show here that anti-PD-L1 treatment added to radiotherapy was not enough to achieve T cell-mediated memory in UPPL tumors. Stronger T cell activation signals may be required to enhance radiation efficacy in luminal-like bladder cancer.

摘要

肌层浸润性膀胱癌是一种高度致命的疾病,在过去几十年中,患者的生存率并没有显著提高。UPPL 是一种细胞系,可以用来重现膀胱癌的腔型分子亚型,并发现可转化为患者的有效治疗方法。在这里,我们研究了放射治疗和免疫治疗联合治疗在这种最近被描述的 UPPL 荷瘤小鼠中的效果。我们首先描述了基线肿瘤微环境以及放射、抗 PD-L1 和联合治疗的作用。然后,将小鼠的第二肿瘤(第一肿瘤对侧的再挑战肿瘤)重新挑战,以评估免疫记忆。放射治疗减缓了肿瘤的生长。所有治疗方法还降低了中性粒细胞数量,增加了 T 细胞数量。抗 PD-L1 治疗不能与放射治疗协同作用以进一步延迟肿瘤生长。此外,没有一种治疗方法能够产生免疫记忆。这些治疗方法不足以诱导大量持久的记忆细胞池。我们在这里表明,抗 PD-L1 治疗联合放射治疗不足以在 UPPL 肿瘤中实现 T 细胞介导的记忆。可能需要更强的 T 细胞激活信号来增强腔型膀胱癌的放射疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/11174127/84348995dc89/KCBT_A_2365452_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/11174127/9c760583541c/KCBT_A_2365452_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/11174127/151efed1ea49/KCBT_A_2365452_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/11174127/84348995dc89/KCBT_A_2365452_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/11174127/9c760583541c/KCBT_A_2365452_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/11174127/151efed1ea49/KCBT_A_2365452_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/11174127/84348995dc89/KCBT_A_2365452_F0003_B.jpg

相似文献

1
Effects of combined radiotherapy with immune checkpoint blockade on immunological memory in luminal-like subtype murine bladder cancer model.联合放疗和免疫检查点阻断对腔上皮样亚型小鼠膀胱癌模型中免疫记忆的影响。
Cancer Biol Ther. 2024 Dec 31;25(1):2365452. doi: 10.1080/15384047.2024.2365452. Epub 2024 Jun 11.
2
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.CD122 定向白细胞介素-2 治疗膀胱癌的机制不同于 αPD-L1,包括组织选择性 γδ T 细胞激活。
J Immunother Cancer. 2021 Apr;9(4). doi: 10.1136/jitc-2020-002051.
3
ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.ATR 抑制剂 AZD6738 通过增强肝癌肿瘤免疫微环境增强放疗和免疫检查点抑制剂的抗肿瘤活性。
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2019-000340.
4
Anti-PD-L1 antibody retains antitumour effects while mitigating immunotherapy-related colitis in bladder cancer-bearing mice after CT-mediated intratumoral delivery.CT 介导的肿瘤内递送后,抗 PD-L1 抗体在减轻膀胱癌荷瘤小鼠免疫治疗相关结肠炎的同时保留抗肿瘤作用。
Int Immunopharmacol. 2024 Aug 20;137:112417. doi: 10.1016/j.intimp.2024.112417. Epub 2024 Jun 18.
5
Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.用抗 PD-L1 释放肿瘤免疫的刹车,并结合放射治疗用 L19-IL2 推动其加速器,可治愈免疫原性差的肿瘤。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001764.
6
Neoadjuvant radiotherapy in ER, HER2, and triple-negative -specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy.基于人源化肿瘤小鼠的 ER、HER2 和三阴性乳腺癌新辅助放疗增强抗 PD-L1 治疗效果。
Front Immunol. 2024 Apr 29;15:1355130. doi: 10.3389/fimmu.2024.1355130. eCollection 2024.
7
In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.局部放射治疗原位递送 iPSC 来源的树突状细胞可在临床前免疫原性低的肿瘤模型中产生全身抗肿瘤免疫并增强 PD-L1 阻断作用。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2021-002432.
8
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.TIM-3 上调和调节性 T 细胞浸润介导放疗抵抗和 PD-L1 阻断。
Clin Cancer Res. 2018 Nov 1;24(21):5368-5380. doi: 10.1158/1078-0432.CCR-18-1038. Epub 2018 Jul 24.
9
[Efficacy of combined treatment with pirfenidone and PD-L1 inhibitor in mice bearing ectopic bladder cancer xenograft].吡非尼酮与PD-L1抑制剂联合治疗对荷异位膀胱癌异种移植小鼠的疗效
Nan Fang Yi Ke Da Xue Xue Bao. 2024 Feb 20;44(2):210-216. doi: 10.12122/j.issn.1673-4254.2024.02.02.
10
Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy.抗 PD-1/PD-L1 治疗联合放疗的潜在问题和未解决问题。
Tumori. 2021 Aug;107(4):282-291. doi: 10.1177/0300891620940382. Epub 2020 Jul 31.

引用本文的文献

1
Radiolabeled Nanogels: From Multimodality Imaging to Combination Therapy of Cancer.放射性标记的纳米凝胶:从多模态成像到癌症联合治疗
Small Sci. 2025 Jun 19;5(8):2400298. doi: 10.1002/smsc.202400298. eCollection 2025 Aug.

本文引用的文献

1
Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer.从嵌合抗原受体 T 细胞免疫疗法治疗癌症的单细胞分析中获得的见解。
Mil Med Res. 2023 Nov 8;10(1):52. doi: 10.1186/s40779-023-00486-4.
2
Proteomics of immune cells from liver tumors reveals immunotherapy targets.肝癌免疫细胞的蛋白质组学揭示免疫治疗靶点。
Cell Genom. 2023 May 30;3(6):100331. doi: 10.1016/j.xgen.2023.100331. eCollection 2023 Jun 14.
3
Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
膀胱癌的蛋白质基因组学特征揭示了FGFR3突变肿瘤对肿瘤坏死因子相关凋亡诱导配体诱导的凋亡的敏感性。
Eur Urol. 2024 May;85(5):483-494. doi: 10.1016/j.eururo.2023.05.037. Epub 2023 Jun 27.
4
Development of a Molecular-Subtype-Associated Immune Prognostic Signature That Can Be Recognized by MRI Radiomics Features in Bladder Cancer.一种可通过MRI影像组学特征识别的与分子亚型相关的膀胱癌免疫预后特征的开发。
Bioengineering (Basel). 2023 Mar 2;10(3):318. doi: 10.3390/bioengineering10030318.
5
Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer.肌肉浸润性膀胱癌肿瘤浸润免疫谱的特征。
Front Immunol. 2023 Feb 3;14:986598. doi: 10.3389/fimmu.2023.986598. eCollection 2023.
6
Proteomic analysis reveals key differences between squamous cell carcinomas and adenocarcinomas across multiple tissues.蛋白质组学分析揭示了多个组织中鳞癌和腺癌之间的关键差异。
Nat Commun. 2022 Jul 18;13(1):4167. doi: 10.1038/s41467-022-31719-0.
7
T Cell Memory in Infection, Cancer, and Autoimmunity.T 细胞记忆在感染、癌症和自身免疫中的作用。
Front Immunol. 2022 Jan 3;12:811968. doi: 10.3389/fimmu.2021.811968. eCollection 2021.
8
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
9
Discovering dominant tumor immune archetypes in a pan-cancer census.在泛癌普查中发现主要的肿瘤免疫表型。
Cell. 2022 Jan 6;185(1):184-203.e19. doi: 10.1016/j.cell.2021.12.004. Epub 2021 Dec 27.
10
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials.辅助化疗治疗肌层浸润性膀胱癌:随机对照试验个体参与者数据的系统评价和荟萃分析。
Eur Urol. 2022 Jan;81(1):50-61. doi: 10.1016/j.eururo.2021.09.028. Epub 2021 Nov 19.